CSIMarket
 

Fate Therapeutics Inc   (FATE)
Other Ticker:  
 

Fate Therapeutics Inc 's

Competitiveness


 

FATE Sales vs. its Competitors Q3 2023







Revenue Growth Comparisons




Net Income Comparison




<<  FATE Stock Performance Comparisons



*Market share is calculated based on total revenue.

  News about Fate Therapeutics Inc Contracts

Revolutionizing Cancer Treatment: Fate Therapeutics Leads the Charge with Phase 1 Trial of iPSC-Derived CAR T-cell Therapy

San Diego-based biopharmaceutical company Fate Therapeutics, in conjunction with Ono Pharmaceutical Co., recently announced the initiation of a groundbreaking Phase 1 Clinical Trial for cellular immunotherapy FT825/ONO-8250 in patients battling HER2-expressing advanced solid tumors. Encompassing a novel HER2-targeted antigen-binding domain, this innovative product candidate originates from induced pluripotent stem cells (iPSCs).Fate Therapeutics, notable for its transformative work in cell-based cancer immunotherapy, is incorporating an unprecedented seven synthetic controls of cell function into FT825/ONO-8250 in its pursuit of pioneering novel treatments. HER2 (human epidermal growth factor receptor 2) is ...





Who are Fate Therapeutics Inc 's Competitors?





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com